Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

487 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Peet M, Horrobin DF. Peet M, et al. Among authors: horrobin df. Arch Gen Psychiatry. 2002 Oct;59(10):913-9. doi: 10.1001/archpsyc.59.10.913. Arch Gen Psychiatry. 2002. PMID: 12365878 Clinical Trial.
A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E).
Horrobin DF. Horrobin DF. Prog Drug Res. 2002;59:171-99. doi: 10.1007/978-3-0348-8171-5_6. Prog Drug Res. 2002. PMID: 12458967 Review.
Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression.
Murck H, Song C, Horrobin DF, Uhr M. Murck H, et al. Among authors: horrobin df. Int J Neuropsychopharmacol. 2004 Sep;7(3):341-9. doi: 10.1017/S1461145704004249. Epub 2004 Mar 5. Int J Neuropsychopharmacol. 2004. PMID: 15003146 Review.
The effects on plasma, red cell and platelet fatty acids of taking 12 g/day of ethyl-eicosapentaenoate for 16 months: dihomogammalinolenic, arachidonic and docosahexaenoic acids and relevance to Inuit metabolism.
Horrobin D, Fokkema MR, Muskiet FA. Horrobin D, et al. Prostaglandins Leukot Essent Fatty Acids. 2003 May;68(5):301-4. doi: 10.1016/s0952-3278(03)00007-3. Prostaglandins Leukot Essent Fatty Acids. 2003. PMID: 12711245
Eicosapentaenoic acid in treatment-resistant depression.
Puri BK, Counsell SJ, Richardson AJ, Horrobin DF. Puri BK, et al. Among authors: horrobin df. Arch Gen Psychiatry. 2002 Jan;59(1):91-2. doi: 10.1001/archpsyc.59.1.91-a. Arch Gen Psychiatry. 2002. PMID: 11779290 No abstract available.
Rapid improvement of severe anorexia nervosa during treatment with ethyl-eicosapentaenoate and micronutrients.
Ayton AK, Azaz A, Horrobin DF. Ayton AK, et al. Among authors: horrobin df. Eur Psychiatry. 2004 Aug;19(5):317-9. doi: 10.1016/j.eurpsy.2004.06.002. Eur Psychiatry. 2004. PMID: 15276668 No abstract available.
A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms.
Peet M, Horrobin DF; E-E Multicentre Study Group. Peet M, et al. Among authors: horrobin df. J Psychiatr Res. 2002 Jan-Feb;36(1):7-18. doi: 10.1016/s0022-3956(01)00048-6. J Psychiatr Res. 2002. PMID: 11755456 Clinical Trial.
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment.
Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, Appel C, Mckee HM, Vaddadi KS, Horrobin DF. Puri BK, et al. Among authors: horrobin df. Neuroreport. 2002 Jan 21;13(1):123-6. doi: 10.1097/00001756-200201210-00029. Neuroreport. 2002. PMID: 11924873 Clinical Trial.
Ethyl-EPA in Alzheimer's disease--a pilot study.
Boston PF, Bennett A, Horrobin DF, Bennett CN. Boston PF, et al. Among authors: horrobin df. Prostaglandins Leukot Essent Fatty Acids. 2004 Nov;71(5):341-6. doi: 10.1016/j.plefa.2004.07.001. Prostaglandins Leukot Essent Fatty Acids. 2004. PMID: 15380822 Clinical Trial.
A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.
Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. Vaddadi KS, et al. Among authors: horrobin df. Psychiatry Res. 1989 Mar;27(3):313-23. doi: 10.1016/0165-1781(89)90146-7. Psychiatry Res. 1989. PMID: 2565585 Clinical Trial.
487 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback